Results 181 to 190 of about 59,823 (200)

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients

Annals of Oncology, 2009
G Schackert, T Illmer, M Pfirrmann
exaly  

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Lancet, The, 2019
Martin Misch, Johannes Weller, Horst Urbach   +2 more
exaly  

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

Annals of Oncology, 2003
D Traish, S Ashley, M Brada
exaly  

Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas

Cancer Letters, 2015
Daniel Gélain, JOSÉ Claudio Fonseca Moreira, Alfeu Zanotto-Filho   +2 more
exaly  

Crystal Engineering of Stable Temozolomide Cocrystals

Chemistry - an Asian Journal, 2012
Palash Sanphui
exaly  

Temozolomide for immunomodulation in the treatment of glioblastoma

Neuro-Oncology, 2018
Duane Mitchell, Alicia Hou, Farhad Dastmalchi   +2 more
exaly  

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas

Journal of Neuro-Oncology, 2015
Fausto Bogazzi, Marco Losa, Salvatore Cannavo   +2 more
exaly  

Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas

Expert Review of Neurotherapeutics, 2010
Marc Chamberlain
exaly  

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)

Annals of Oncology, 2006
M Crump, M E Trudeau, D Charpentier
exaly  

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Annals of Oncology, 2014
C Dalban, L Taillandier, F Ghiringhelli   +2 more
exaly